The weight loss drug boom isn't over yet — here's what to expect in the year ahead
Publishing timestamp: 2023-12-17 08:00:01
Summary
The article discusses the upcoming year as a pivotal one for weight loss drugs. It mentions that Eli Lilly and Novo Nordisk will face supply issues with their treatments and are expected to release crucial clinical trial data. The article also discusses the potential for the weight loss drug market to expand and mentions other companies, such as Pfizer and Amgen, that could alter the competitive landscape. It highlights the potential for increased insurance coverage and the cardiovascular benefits of certain drugs. The article also mentions the possibility of acquisitions or partnerships in the industry.
Sentiment: MIXED
Tickers: LLY, AMGN, NOVO.B-DK, ROG-CH, ALT, PFE, UNDEFINED, AZN-GB,
Keywords: roche holding ag, amgen inc, health care industry, business news, business, biotech and pharmaceuticals, weight management, astrazeneca plc, structure therapeutics inc, biotechnology, united states, pfizer inc, altimmune inc, eli lilly and co, pharmaceuticals, novo nordisk a/s, breaking news,
Source: https://www.cnbc.com/2023/12/17/weight-loss-drugs-2024-expectations-for-wegovy-ozempic-zepbound.html